TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OptiBiotix Health ( (GB:OPTI) ) has provided an announcement.
OptiBiotix Health plc reported a significant growth in its financial performance for the first half of 2025, with gross revenue increasing by 102% and gross profit by 173% compared to the same period in 2024. The company expanded its customer base, particularly in Asia and the USA, and anticipates continued sales momentum with product launches and partnerships. Cost reductions and improved margins are expected to enhance profitability, positioning OptiBiotix for substantial growth in shareholder value.
More about OptiBiotix Health
OptiBiotix Health plc, established in March 2012, operates in the life sciences industry, focusing on developing compounds that modify the human microbiome to prevent and manage diseases like obesity, cardiovascular disease, and diabetes. The company collaborates with international food and healthcare supplement companies to integrate its microbiome modulators into various food products and drinks, while also developing its own consumer supplements and health products.
Average Trading Volume: 314,462
Technical Sentiment Signal: Sell
Current Market Cap: £11.88M
For detailed information about OPTI stock, go to TipRanks’ Stock Analysis page.